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However Much You Are Willing to Spend on Bivalirudin*Rod H. Stables, DMSEE PAGE 214T here is now general agreement, based onresearch from the last 20 years, that the useof bivalirudin—rather than heparin—confers
no advantage in terms of reduced ischemic events
(1,2). Indeed, an increased rate of acute stent throm-
bosis (and the associated sequelae of myocardial
infarction and unplanned revascularization) has
been a consistent ﬁnding with bivalirudin treatment,
particularly in the recent trials examining primary
percutaneous coronary intervention (PCI) (3–5).
Our recent trial, HEAT-PPCI (Unfractionated
Heparin Versus Bivalirudin in Primary Percutaneous
Coronary Intervention) (4), recruited a near “all-
comers” population, and the observed adverse
event rates more closely matched institutional norms
and the results reported by national registries (e.g.,
1-month mortality: HEAT-PPCI 4.7%, HORIZONS-
AMI 2.6%). The relative risk of acute stent throm-
bosis (AST) was less dramatic in HEAT-PPCI
(3.26; 95% conﬁdence interval [CI]: 1.32 to 8.07)
than in HORIZONS-AMI (Harmonizing Outcomes with
RevasculariZatiON and Stents in Acute Myocardial
Infarction) (5.19; 95% CI: 1.79 to 15.08) or EUROMAX
(European Ambulance Acute Coronary Syndrome
Angiography Trial) (6.11; 95% CI: 1.37 to 27.74), but
the study may give a good estimate of current, “real-
world,” absolute AST event rates for a strategy of
procedural monotherapy with bailout glycoprotein
IIb/IIIa inhibitor (GPI) use (and in the absence of
systematic use of heparin in the bivalirudin arm).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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(<$70,000).Bivalirudin has a loyal cadre of enthusiastic
users. The drug has attractive features, including a
well-established procedural dose regime, a predict-
able biological effect, no need for monitoring with
tests of clotting function, and a short half-life. Use
of bivalirudin rather than heparin in higher doses
(100 to 140 U/kg body weight) will almost certainly
reduce bleeding complications. Because of this, there
will be great interest in the description of a strategy to
reduce or abolish the hazard of AST.In this issue of JACC: Cardiovascular Interventions,
the EUROMAX investigators present an analysis from
their important randomized trial (6). They suggest
that the use of a continued (4 h) infusion of bivalir-
udin at the PCI procedure dose is effective in the
prevention of AST. This idea has strong biological
plausibility, and a similar effect has been reported in
the presentation of results from BRIGHT (BivaliRudin
in Acute Myocardial Infarction vs Glycoprotein IIb/
IIIa and Heparin: a Randomised Controlled Trial), a
Chinese trial—albeit with a different form of bivalir-
udin and at a lower infusion dose (7).
The EUROMAX investigators have, to their credit,
noted that their ﬁndings should be treated with
caution and cannot be considered as secure without
new, prospective trials. This is an important obser-
vation. There were only 16 AST events in the study.
This makes it very hard to identify the true, inde-
pendent effect of any individual factor.
Beyond problems with statistical power, the situ-
ation is further complicated by the characteristics of
patients with an AST event. The vast majority of AST
was seen in patients randomized to bivalirudin ther-
apy (12 events vs. 2 events). The rate of GPI use in
these bivalirudin-treated AST patients was very high
(9 of 12, 75%) when compared with the overall rate of
GPI in the bivalirudin arm (12%). This may be related
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222to a higher rate of procedural complications reported
for these patients. With the low number of absolute
events, this may represent the play of chance, but
the possibility of a bivalirudin-related, systematic
increased rate of procedural issues prompting sub-
sequent AST cannot be excluded.
Interventional cardiologists who are tempted to
adopt a strategy of bivalirudin therapy with a
continued high-dose infusion (BIV-HIGH) should
study the outcome data presented in Table 3 of the
paper by the EUROMAX investigators (6), but not
highlighted in the text of the report. The BIV-HIGH
patients were compared with the patients random-
ized to heparin. BIV-HIGH therapy provided no sig-
niﬁcant advantage with respect of any of the primary
or secondary outcomes—ischemic major adverse car-
diovascular events, bleeding, or combined net clinical
beneﬁt measures. Because the numbers in this study
are small, it is difﬁcult to draw ﬁrm conclusions;
however, some reduction in bleeding is counter-
balanced by increased major adverse cardiovascular
events related to all-cause mortality.
There is also the issue of cost. The cost of bivalir-
udin therapy is a function of the number of vials
purchased, and this will be related to a number of
factors, including the body weight of the patient
and the duration of the PCI procedure. The sys-
tematic use of additional infusions in the pre- and/orpost-procedural phases will make the relative cost
(compared with heparin) range to more than 1,000
or 1,500 fold. There would also be other cost impli-
cations, for example, nursing time. The aim of this
investment would be to achieve AST rate equivalence
to a drug that costs only pence.
Enthusiasts for bivalirudin believe that the use
of this drug reduces bleeding. This advantage has
been reported in many studies. The bleeding risk
of heparin seems to be related to the rate of
concomitant use of glycoprotein IIb/IIIa receptor
antagonists and to heparin dosing. In recent studies
using lower-dose heparin (70 U/kg body weight) and
with “bailout” glycoprotein IIb/IIIa receptor use,
bleeding rates are similar to those observed with
bivalirudin (3,8).
It is possible that the use of a post-procedural
infusion of bivalirudin may abolish the additional
stent thrombosis hazard, but any potential trials to
examine this question should include a comparator
arm using modest-dose heparin therapy and a robust
cost-beneﬁt analysis.
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